Industry Trends & Resources

Visuotinis klinikinių tyrimų palaikymas: ryšys per sienas

Visuotinis klinikinių tyrimų palaikymas: ryšys per sienas

Connecting Patients, Sites and Study Teams Across Borders Clinical trials are becoming increasingly global. Patients may travel across cities, states, or even international borders to access specialized treatments and participate in studies. While expanding a trial geographically can help sponsors reach more diverse patient populations, it also introduces another layer

Skaityti daugiau »
Pasaulinis plaučių vėžio atminimo mėnuo: pagerbiame žuvusiųjų atminimą ir puoselėjame viltį per klinikinius tyrimus

Pasaulinis plaučių vėžio atminimo mėnuo

World Lung Cancer Remembrance Month: Honoring Lives, Advancing Hope Through Clinical Trials Every August, World Lung Cancer Remembrance Month serves as a time to honor the lives of those affected by lung cancer, support patients and caregivers navigating the disease today, and recognize the ongoing research that continues to change

Skaityti daugiau »
Onkologinių tyrimų operacinės realybės valdymas: kodėl rėmėjams svarbu pasirūpinti kelionių ir išlaidų administravimu

Navigavimas onkologinių tyrimų operacinėje realybėje

Navigating the Operational Reality of Oncology Trials: Why Travel & Expense Design Matters to Sponsors Oncology clinical trials are designed around scientific rigor, regulatory precision, and the promise of advancing care. But beneath the protocol design and endpoints sits a quieter determinant of success: whether participants can realistically stay engaged

Skaityti daugiau »
Sarcoma Awareness Month: Advancing Hope Through Research

Sarcoma Awareness Month: Advancing Hope Through Research

Sarcoma Awareness Month: Advancing Hope Through Research, Collaboration, and Clinical Trials Every July, Sarcoma Awareness Month brings attention to one of the rarest and most diverse forms of cancer while recognizing the patients, families, clinicians, researchers, and advocates dedicated to improving outcomes. Sarcomas account for approximately 1% of adult cancers

Skaityti daugiau »
Pereiti prie turinio